Andrew Varghese, President USA ROTOP Pharmaka GmbH

ROTOP Pharmaka GmbH is pleased to announce new investments secured from GENUI & SHS Capital along with the appointment of Andrew Varghese as its new President of ROTOP USA.
Founded in 2000 and based in Dresden-Rossendorf, ROTOP is a leading manufacturer of radiopharmaceutical products. With the recent growth in radiopharmaceuticals and its advantage to achieve targeted therapy with minimal side-effects, ROTOP had developed and brought multiple radiopharmaceuticals into Germany and into the European and global markets. Considering the growth in new innovative products being developed for both diagnosis and therapy, there is a significant need for stronger expertise in API development, radiochemistry, radiopharmacy labelling and product distribution logistics. ROTOP with its deep expertise in these areas for 25 years, began expanding its CDMO offering two years ago.

With the new investments ROTOP secured from GENUI & SHS Capital, ROTOP is further positioned to expand the footprint and be a significant player in the CDMO space to provide clinical and commercial batch volumes both in cold and hot products. With the new investments the manufacturing volume is expected to grow more than ten times. With ROTOP’s deep domain expertise in radiopharmaceutical development, quality & regulatory know-how to support clinical trials, scaling from study volumes to commercial manufacturing volumes and strong logistics network in Europe, ROTOP wants to be a partner of choice for radiopharmaceutical innovators.

With this vision in mind, ROTOP has appointed Andrew Varghese as President, ROTOP USA. Andrew Varghese served at GE Healthcare for 16 years and his roles spanned from research, product development, and product management to leading various global teams. At GE Healthcare, Andrew led its Osteoporosis and Metabolic health product & service business. Andrew also served as General Manager for GE Healthcare’s Research Operations where he helped built out the infrastructure for the internal Clinical Research Organization (CRO). In addition to his time at GE Healthcare, Andrew served as Vice President & General Manager of Trudell Medical International, a respiratory device business, where he was responsible for creating and executing the growth strategy. Under Andrew’s leadership, new products were introduced globally and commercial channels were established across Europe, Asia, and the Middle East and new B2B partnerships were created with pharmaceutical companies providing new revenue streams. With Andrew’s extensive industry experience and ability to create win-win partnerships, he is poised to realize ROTOP’s vision for expansion.

“With GENUI & SHS’s investment to support ROTOP’s vision to expand, we are excited for Andrew Varghese to join ROTOP and help us grow and strengthen our partnerships,” said Jens Junker, CEO of ROTOP. Andrew will be based in Raleigh, NC.

“With the race to discover new radiopharmaceuticals, the field of nuclear medicine is undergoing a renaissance and I am thrilled to join ROTOP and enable pharmaceutical partners and clinicians to bring clinical innovations to patients,” said Andrew Varghese.